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Abstract
Background: Soil-transmitted helminths (STHs) including Ascaris lumbricoides, Necator americanus, Ancylostoma spp.
and Trichuris trichiura are cause of significant global morbidity. To mitigate their disease burden, at-risk groups in
endemic regions receive periodic mass drug administration using anthelmintics, most commonly albendazole and
mebendazole. Assessing the efficacy of anthelmintic drugs is important for confirming that these regimens are working
effectively and that drug resistance has not emerged. In this study we aimed to characterise the therapeutic efficacy of
albendazole against Ascaris spp. and N. americanus in Timor-Leste, using a quantitative polymerase chain reaction (qPCR)
method for parasite detection and quantification.
Results: A total of 314 participants from 8 communities in Timor-Leste provided stool samples before and 10–14 days
after the administration of a single 400 mg dose of albendazole. Helminth infection status and infection intensity
(measured in Ct-values and relative fluorescence units) were determined using qPCR. Efficacy was determined
by examining the cure rates and infection intensity reduction rates. Albendazole was found to be highly efficacious
against Ascaris spp., with a cure rate of 91.4% (95% CI: 85.9–95.2%) and infection intensity reduction rate of 95.6%
(95% CI: 88.3–100%). The drug was less efficacious against N. americanus with a cure rate of 58.3% (95% CI: 51.4–64.9%)
and infection intensity reduction rate of 88.9% (95% CI: 84.0–97.0%).
Conclusions: The observed cure rates and infection intensity reduction rates obtained for Ascaris spp. and to a lower
extent N. americanus, demonstrate the continued efficacy of albendazole against these species and its utility as a mass
chemotherapy agent in Timor-Leste. Furthermore, this study demonstrates the usefulness of qPCR as a method
to measure the efficacy of anthelminthic drugs. Additional research is necessary to translate Ct-values into eggs per
gram in a systematic way.
Trial registration: Australian and New Zealand Clinical Trials Registry 12614000680662 (registered 27 June 2014).
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Background
More than 1.4 billion people worldwide are estimated to
suffer from infection with soil-transmitted helminths
(STHs) [1]. The infective stages of these parasites thrive
in the warm moist soils of tropical regions, and are
transmitted through oral ingestion or skin penetration
[2]. These modes of transmission mean that the most af-
fected individuals are from poor communities that lack
the adequate water, hygiene and sanitation necessary to
prevent transmission and reinfection. Ascaris lumbricoides
(roundworm),Trichuris trichiura (whipworm), and Necator
americanus and Ancylostoma spp. (hookworms) are the
most common STHs. They cause significant morbidity, par-
ticularly in children, who are commonly co-infected with
multiple species [2]. Chronic infection can retard child
growth and development, and infected individuals can suf-
fer malnutrition, growth stunting and reduced cognitive
abilities and intellectual capacity [2, 3]. Studies have indi-
cated the significant adverse impact of STH infection on
school attendance and performance and future economic
productivity, although the health impact of STH infection
is being debated [4–6].
The World Health Organization (WHO) has set goals
to reduce STH-associated morbidity in children to a
level at which it is no longer considered a public health
problem [7]. To achieve this, populations at risk in en-
demic areas, mainly school-age children, are targeted
with mass chemotherapy using anthelmintic drugs at ei-
ther six monthly or yearly intervals depending on infec-
tion prevalence [8, 9]. The current recommended drugs
are the benzimidazole drugs, albendazole and mebendazole
[8], which are highly efficacious against A. lumbricoides
with a recent meta-analysis indicating pooled cure rates of
95.7 and 96.2%, respectively, and egg reduction rates of 98.
5 and 98.0%, respectively [10]. Albendazole is also effica-
cious against hookworm, with a pooled cure rate of 79.5%
and egg reduction rate of 89.6%, compared to a cure rate of
32.5% and egg reduction rate of 61.0% for mebendazole
[10]. Both drugs have poor efficacy against T. trichiura,
with pooled cure rates of 30.7 and 42.1% for albendazole
and mebendazole, respectively [10]. The WHO, inter-
national partners and pharmaceutical companies are com-
mitted to scaling up mass drug administration so that by
2020, 75% of at-risk children are being dewormed [7]. In
2016 alone, over 470 million schoolchildren were treated
with anthelmintic drugs in endemic countries, correspond-
ing to 69.5% of children at risk [11].
Greater usage of albendazole entails greater selection
pressure of the drug for resistant parasite strains. There-
fore, with the scaling up of mass drug administration
programs, there are growing concerns over the potential
for drug resistance to emerge in humans, similar to what
has happened in other animals. In livestock, resistance
to benzimidazoles is widespread, having emerged from
the large-scale use of the drugs [12–14]. Monitoring the
efficacy of anthelmintic drugs in order to detect the po-
tential emergence of resistance in human populations is
imperative to ensure that mitigation strategies can be
promptly implemented to preserve the effectiveness of
mass deworming campaigns [15]. STH are generally di-
agnosed using microscopy-based methods - most com-
monly the Kato-Katz method - to detect helminth eggs
in stool. However, this method is known to have low
sensitivity in lower-intensity and lower transmission set-
tings, and requires examination of multiple samples to
improve sensitivity [16]. Recently, quantitative polymer-
ase chain reaction (qPCR)-based methods have been de-
veloped for the diagnosis and quantification of STH and
validated as more sensitive than the conventional mi-
croscopy approaches [17–21].
The aim of this study was to determine the efficacy of
a single dose of albendazole against STH infections
using quantitative polymerase chain reaction (qPCR) for
the detection and quantification of Ascaris spp., N.
americanus, Ancylostoma spp. and T. trichiura, in the
context of the implementation of the WASH for
WORMS study, a cluster randomised controlled trial
(RCT) in rural communities in Timor-Leste [17, 22].
Timor-Leste is a lower middle income country [23],
where malnutrition and infectious diseases (such as
pneumonia, diarrhea, malaria, tuberculosis and dengue)
remain significant health problems [24]. The WASH for
WORMS RCT which included community distribution
of albendazole every 6 months for 2 years, at a time
when no regular mass deworming was being imple-
mented in the country [22]. The previous “Lumbriga…
Mak Lae Duni” (Worms, no way!) mass drug adminis-
tration program was implemented from 2005 to 2008
and was resumed in 2015. To our knowledge, this is the
first albendazole efficacy study to be conducted in
Timor-Leste and the first efficacy study to use qPCR for
the calculation of cure rates and infection intensity
reduction rates.
Methods
Study setting and data collection
This efficacy study was conducted from January 2012 to
March 2013, in 8 communities in Manufahi municipality
of Timor-Leste, which had been enrolled in the WASH
for WORMS cluster RCT [22]. All community members
were eligible for participation in the efficacy study, ex-
cluding women in the first trimester of pregnancy and
children under 12 months of age. Baseline stool samples
were collected for assessment of infection status and in-
tensity, and individuals were subsequently given a single
400 mg dose of albendazole. Drug distribution was done
by trained field workers. Children aged under 2 years
were given half the dose. Between 10 and 14 days later, a
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second stool sample was collected to again determine in-
fection status and intensity.
Sample size was calculated based on the following
current recommendations [25]. Tree-based methods in-
dicated that a minimum of 200 subjects (independent of
infection status) is recommended to be able to detect a
normal vs reduced efficacy based on faecal egg count re-
duction (FECR) [25]. Furthermore, WHO recommends a
sample of 50 positive individuals for each parasite tested
[26]. To achieve the necessary sample size and consider-
ing a compliance rate of 0.75 at each stool collection
time point and estimated prevalences of 30% for Ascaris
spp. and 50% for hookworm (based on studies in neigh-
bouring Indonesia), we enrolled the first 8 of the 24
communities participating in the WASH for WORMS
trial into the efficacy study, corresponding to approxi-
mately 500 eligible participants [27–29].
Assessment of STH infection
Once collected, the stool samples were preserved at room
temperature in 5% (weight/volume) potassium dichromate
and transported to the QIMR Berghofer Medical Research
Institute in Brisbane, Australia. The presence and intensity
of protozoa and STH infection in stool samples was deter-
mined using qPCR methods as described previously [17]. In
short, DNA extracted from samples that were spiked with a
known amount of the plasmid used as positive control was
run in a pentaplex real-time PCR reaction for detection and
quantification of Ascaris spp., N. americanus, Ancylostoma
spp. and T. trichiura [17]. The Rotor-Gene 6000 (Qiagen,
Melbourne VIC, Australia) was used for all PCR assays
[17]. Cycle threshold (Ct) values obtained using qPCR cor-
respond to the amplification cycle at which the detected
signal exceeds the background level. For a stool sample to
be considered positive for infection, a limit of detection
cut-off was set at 31 for Ascaris spp. and 35 for N. ameri-
canus, Ancylostoma spp. and T. trichiura, to ensure
consistency with previously published PCRs [17]. For each
qPCR assay, two runs were performed to generate two Ct-
values. The arithmetic mean was taken of these two values
to produce a single value. For calculation of intensity re-
duction rates, Ct-values were then converted to infection
intensity measured in Relative Fluorescence Units (RFU)
based on an assumed 100% reaction run efficiency, pro-
vided by the Rotorgene Q software (Infection intensity as
determined by qPCR ¼ 100:2980Ctþ9:81 RFU ) [17]. Sam-
ples which did not record a Ct-value were assigned an
infection intensity value of 0.
Statistical analysis
Pre- and post-treatment prevalence were compared using
Chi-square test, or Fischer’s exact test in cases when fre-
quency values were below 5. Only individuals who were
positive at the pre-treatment time point were included in
calculations of cure rate and infection intensity reduction
rate derived from PCR.
Cure rate was calculated using the following formula:
No: of individuals positive pre-treatment and negative post-treatment
No: of individuals positive pre-treatment
 100
95% binomial exact confidence intervals were calcu-
lated for both prevalence and cure rate. Age group (1–5
years; 6–11 years; 12–17 years; 18–64 years; and > 65
years) and sex were examined separately for potential as-
sociations with the probability of being cured, using the
Wald Chi-square test adjusted for community-level clus-
tering. The impact of baseline prevalence and baseline
infection intensity (Ct-values) on cure rate was assessed
using a multivariate logistic regression model, adjusted
for age and sex, with a robust standard error adjusted
for clustering at the community level.
Infection intensity reduction rate was calculated
using the following formula as per WHO recommen-
dations [25, 26]:




Confidence intervals for infection intensity reduction
rate were calculated using a bootstrap re-sampling
method with 10,000 replicates. The impact of baseline
infection intensity (Ct-values) on infection intensity
reduction rate was assessed using a multivariate linear
regression model, adjusted for age and sex, with a ro-
bust standard error adjusted for clustering at the
community level.
Fig. 1 Efficacy study diagram
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All analyses were conducted using Stata version 11.0
(College Station, TX, USA). A 5% significance limit was
used for all analyses.
Results
Population under study
From the 8 communities enrolled, 678 individuals were
present and eligible for study participation, of whom 599
(88.3%) agreed to participate. In total, 314 individuals
provided both pre- and post-treatment stool samples
and were included in the efficacy analysis presented here
(Fig. 1). Participants ranged in age from 1 to 72 years,
with a mean of 21 years. Of the study participants 54.8%
were females and 45.2% were males.
The most prevalent species was N. americanus at 69.
4% (95% CI: 64.1–74.2%), followed by Ascaris spp. at 51.
6% (95% CI: 46.1–57.1%). Ancylostoma spp. (2.6%; 95%
CI: 1.1–5.0%) and T. trichuria (1.3%; 95% CI: 0.3–3.2%)
both had a low prevalence in the study population. For
Ascaris spp., community-level prevalence ranged from
19.3% (95% CI: 10.9–31.8%) to 80.5% (95% CI: 65.3–90.
0%), with a mean community-level prevalence of 54.2%.
For N. americanus, community-level prevalence ranged
from 52.5% (95% CI: 40.0–64.5%) to 87.8% (95% CI: 73.
6–94.9%), with a mean community-level prevalence of
72.6%.
Albendazole efficacy - cure rates and reduction in intensity
As shown in Table 1, the cure rate for Ascaris spp. was
91.4% (95% CI: 85.9–95.2%), and the cure rate for N.
americanus was 58.3% (95% CI: 51.4–64.9%). The cure
rate for Ancylostoma spp. was 100% (95% CI: 68.7–
100%) and for T. trichiura was 50% (95% CI: 67.6–93.
4%); due to the low number of individuals infected with
Ancylostoma spp. and T. trichiura, further analyses were
not performed for these helminths.
Cure rates stratified by age group and sex are presented
in Table 1. There was no significant difference in cure rate
between males and females for either N. americanus (54.
8% vs 61.4%, χ2 = 1.77, df = 1, P = 0.18) or Ascaris spp.
(89.2% vs 93.2%, χ2 = 2.19, df = 1, P = 0.14). Similarly, age
was not associated with being cured, with no statistically
significant difference between age groups for either N.
americanus (χ2 = 1.88, df = 4, P = 0.76) or Ascaris
spp. (χ2 = 5.71, df = 4, P = 0.22).
For N. americanus, community-level baseline preva-
lence was negatively and significantly associated with
cure: for a 1% increase in baseline prevalence, the odds
of being cured decreased by 3% (OR = 0.97, 95% CI: 0.
94–0.99, P = 0.03). Baseline infection intensity (Ct-value)
was not associated with cure. For Ascaris spp., neither
baseline community-level prevalence nor baseline infec-
tion intensity (Ct-value) were associated with cure. Age
and sex were not associated with cure for either N.
americanus or Ascaris spp. Full results of the multivari-
able analysis are shown in Table 2.
Table 1 Cure rates for N. americanus and Ascaris spp., overall and across sex and age groups
Necator americanus Ascaris spp.
n Cure rate (%) (95% CI) χ2 P-value n Cure rate (%) (95% CI) χ2 P-value
Overall 218 58.3 (51.4–64.9) 162 91.4 (85.9–95.2)
Sex 1.77 0.184 2.19 0.139
Male 104 54.8 (44.7–64.6) 74 89.2 (79.8–95.2)
Female 114 61.4 (51.8–70.4) 88 93.2 (85.7–97.5)
Age group (years) 1.88 0.758 5.71 0.222
1–5 35 60 (42.1–76.1) 40 92.5 (79.6–98.4)
6–11 64 62.5 (49.5–74.3) 51 88.2 (76.1–95.6)
12–17 29 58.6 (38.9–76.5) 22 95.5 (77.2–99.9)
18–64 75 52 (40.2–63.9) 43 93.0 (80.9–98.5)
65+ 15 66.7 (38.4–88.2) 6 83.3 (35.9–99.6)
Abbreviations: n, number of individuals positive pre-treatment; CI, confidence interval
Table 2 Results of multivariate logistic regression for infection cure
Odds ratio 95% CI P-value
Necator americanus
Baseline prevalence in community (%) 0.97 0.94–0.99 0.029
Baseline infection intensity (Ct-value) 1.04 0.94–1.14 0.474
Age (years) 0.99 0.98–1.01 0.463
Female sex 0.76 0.43–1.32 0.327
Ascaris spp.
Baseline prevalence in community (%) 0.98 0.95–1.02 0.448
Baseline infection intensity (Ct-value) 1.02 0.94–1.12 0.596
Age (years) 1.00 0.97–1.03 0.975
Female sex 0.56 0.18–1.75 0.321
Abbreviation: CI, confidence interval
Bold indicates statistical significance
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There was a significant decrease in infection intensity
(RFU) for both STH species following treatment, with
an infection intensity reduction rate for Ascaris spp. of
95.6% (95% CI: 88.3–100%) and 88.9% (95% CI: 83.0–97.
0%) for N. americanus (see Table 3). The distribution of
individual infection intensity reduction rates is shown in
Table 4. In short, for both species the large majority of
infections were cured or had an infection intensity reduc-
tion rate higher than 80%. An increase in infection inten-
sity happened in 6.4% of the cases for N. americanus and
in 1.2% of the cases for Ascaris spp.
For Ascaris spp., baseline infection intensity (Ct-value)
was not associated with infection intensity reduction
rate. For N. americanus, a higher baseline infection in-
tensity was associated with a higher intensity reduction
rate (P = 0.04). There was no association between age or
sex and infection intensity reduction rate for either spe-
cies. Full results of the multivariate linear regression
model are shown in Table 5.
Discussion
The findings of this efficacy study are consistent with
earlier reports indicating that a single 400 mg dose of
albendazole is highly efficacious against Ascaris spp. and
less efficacious against hookworm [30]. While our cure
rate for Ascaris spp. is comparable to previous reports,
our detected cure rate for N. americanus was lower [30].
The lower cure rate obtained for N. americanus in this
study is likely to be due to the higher diagnostic sensitivity
of qPCR as compared to microscopy-based techniques
that are generally used in efficacy studies, rather than im-
plicating the existence of emerging benzimidazole resist-
ance. That is, the lower sensitivity of microscopy relative
to qPCR could mean that previously reported cure rates
are over-estimated, as an individual may be misclassified
as cured when in fact their faecal egg count was very low
and not detected by microscopy. This is particularly true
for hookworm, given that allowing the smear to stand for
too long can result in the collapse and disappearance of
hookworm eggs but not those of Ascaris spp. [31]
While cure rate is usually one of the indicators calcu-
lated in efficacy studies, it is not the best measure of
drug efficacy, as it depends on baseline intensity and is
influenced by the sensitivity of the diagnostic technique
[32]. Therefore, current WHO guidelines recommend
using a measure of intensity reduction - the faecal egg
count reduction (FECR) - as the appropriate indicator of
efficacy [26]. WHO guidelines stipulate that the FECR
rate should exceed 95% in the case of A. lumbricoides
and 90% in the case of hookworm [26, 33]. Because we
employed qPCR as a diagnostic technique, infection in-
tensity reduction rates were calculated based on PCR in-
tensity values. Given that we were unable to also use
microscopy methods in these samples we were not able
to measure intensity in eggs per gram, hence the main
limitation of this study is that our infection intensity re-
duction rate values are not directly comparable to FECR
rates previously reported in the literature. However,
given that both these parameters measure the propor-
tional reduction in parasite load within a sample, and in
the absence of a microscopic comparator allowing con-
version of Ct to eggs per gram, we feel it is appropriate
to apply thresholds pertaining to FECR rates to our re-
sults, as a first step in the use of qPCR for drug efficacy
Table 3 Infection intensity values before treatment, after treatment and reduction in infection intensity
Pre-intervention mean infection intensity,
RFU (95% CI)
Post-intervention mean infection intensity,
RFU (95% CI)
Infection intensity reduction
rate (%) (95% CI)
N. americanus (n = 218) 18,283 (13,251–23,316) 2024 (505–3,543) 88.9 (84.0–97.0)
Ascaris spp. (n = 162) 1,517,583 (1,124,742–1,910,424) 67,696 (0–200,926) 95.5 (88.3–100.0)
Abbreviations: n, number of individuals positive pre-treatment; RFU, relative fluorescent units
Table 4 Distribution of individual infection intensity reduction
rates





100 (cured) 127 (58.3) 148 (91.4)
80–99.9 58 (26.6) 10 (6.2)
60–79.9 12 (5.5) 1 (0.6)
40–59.9 4 (1.8) 0
20–39.9 2 (0.9) 1 (0.6)
0–19.9 1 (0.5) 0
Increase in infection intensity 14 (6.4) 2 (1.2)






Baseline infection intensity (Ct-value) -31.8 -61.5– -2.1 0.039
Age (years) -0.6 -2.2–0.9 0.371
Female sex 38.7 -6.6–84.1 0.083
Ascaris spp.
Baseline infection intensity (Ct-value) -0.20 -0.55–0.16 0.238
Age (years) 0.09 -0.30–0.48 0.594
Female sex -9.90 -28.87–9.08 0.257
Abbreviation: CI, confidence interval
Bold indicates statistical significance
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studies. Our infection intensity reduction rates were
above reference efficacy thresholds for Ascaris spp. and
just under the threshold for N. americanus, which sug-
gest the continued efficacy of albendazole against these
STH infections. In order for qPCR to be used as a quan-
titative method in efficacy studies where changes in in-
fection intensity are the designated endpoints, additional
research directly comparing infection intensity by mi-
croscopy and qPCR is needed. This will allow the
conversion of Ct-values into eggs per gram, the estab-
lishment of appropriate thresholds for infection intensity
reduction rates derived from qPCR to determine drug
efficacy, and also the identification of qPCR intensity
cut-offs corresponding to low, moderate and high inten-
sity infection. In previous work infection intensity was
derived by converting Ct-values in eggs per gram, using
standard curves generated by qPCR assays undertaken
on fresh hookworm and Ascaris spp. eggs. These were
then used to interpolate eggs per gram from the PCR
Ct-values obtained for the field samples [17]. Since this
work was done, a number of potential confounding fac-
tors have been identified, including DNA extraction
methods and stool preservative. A notable example is
that we have observed that hookworm eggs preserved in
potassium dichromate, as was the case in our field sam-
ples, can embryonate with storage, potentially resulting
in an overestimation of infection intensity. Additional
work is necessary to take into account storage condi-
tions of field samples as was recently reported by
Papaiakovou et al. [34]. Besides increased sensitivity, an
additional advantage of the use of qPCR is that allows
identification of the different hookworm species present
in the population under study, which is not possible with
microscopy. This will lead to a more refined understand-
ing of albendazole efficacy against specific hookworm
species, each of which can cause different levels and
types of morbidity, and in the case of A. ceylanicum may
require a One Health approach to overall control [35].
Conclusion
As the first albendazole efficacy study to be conducted in
Timor-Leste, the results of this study confirm the utility of
this drug as a chemotherapeutic agent in the region. Fur-
thermore, it demonstrates that qPCR can be effectively
used to determine infection intensity reduction rates. In
the future, this study will provide a useful point of com-
parison to establish whether there is any emerging resist-
ance to albendazole in the context of mass chemotherapy
campaigns that have recently restarted in Timor-Leste.
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